Extension of in vivo half-life of biologically active molecules by XTEN protein polymers
XTEN™ is a class of unstructured hydrophilic, biodegradable protein polymers designed to increase the half-lives of therapeutic peptides and proteins. XTEN polymers and XTEN fusion proteins are typically expressed in Escherichia coli and purified by conventional protein chromatography as monodispers...
Gespeichert in:
| Veröffentlicht in: | Journal of controlled release 2016-10, Vol.240, p.52-66 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 66 |
|---|---|
| container_issue | |
| container_start_page | 52 |
| container_title | Journal of controlled release |
| container_volume | 240 |
| creator | Podust, Vladimir N. Balan, Sibu Sim, Bee-Cheng Coyle, Michael P. Ernst, Ulrich Peters, Robert T. Schellenberger, Volker |
| description | XTEN™ is a class of unstructured hydrophilic, biodegradable protein polymers designed to increase the half-lives of therapeutic peptides and proteins. XTEN polymers and XTEN fusion proteins are typically expressed in Escherichia coli and purified by conventional protein chromatography as monodisperse polypeptides of exact length and sequence. Unstructured XTEN polypeptides have hydrodynamic volumes significantly larger than typical globular proteins of similar mass, thus imparting a bulking effect to the therapeutic payloads attached to them. Since their invention, XTEN polypeptides have been utilized to extend the half-lives of a variety of peptide- and protein-based therapeutics. Multiple clinical and preclinical studies and related drug discovery and development efforts are in progress. This review details the most current understanding of physicochemical properties and biological behavior of XTEN and XTENylated molecules. Additionally, the development path and status of several advanced drug discovery and development efforts are highlighted.
[Display omitted] |
| doi_str_mv | 10.1016/j.jconrel.2015.10.038 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826648729</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365915302054</els_id><sourcerecordid>1826648729</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-8b72cd4980fcd3d5a4d13e9b8ccbaa6e229b79ac6148eab96e4018f6395492fa3</originalsourceid><addsrcrecordid>eNqFkM1qGzEUhUVpqB23j9CiZTfjSqOfkVYlBOcHQrNxwTuh0dxpZTQjVxqb-O0jYzfbrC4cvqN79SH0lZIlJVT-2C63Lo4JwrImVJRsSZj6gOZUNaziWouPaF44VTEp9Axd57wlhAjGm09oVkuuG83oHG1WLxOM2ccRxx77ER_8IeK_NvRV8D2cwtbHEP94Z0M4YusmfwA8xABuHyDj9og369UvvEtxgtLfxXAcIOXP6Kq3IcOXy1yg33er9e1D9fR8_3h781Q5QcVUqbapXce1Ir3rWCcs7ygD3SrnWmsl1LVuG22dpFyBbbUETqjqJdOC67q3bIG-n98tB_zbQ57M4LODEOwIcZ8NVbWUXDW1Lqg4oy7FnBP0Zpf8YNPRUGJOUs3WXKSak9RTXKSW3rfLin07QPfW-m-xAD_PAJSPHjwkk52H0UHnE7jJdNG_s-IVrkeMGg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826648729</pqid></control><display><type>article</type><title>Extension of in vivo half-life of biologically active molecules by XTEN protein polymers</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Podust, Vladimir N. ; Balan, Sibu ; Sim, Bee-Cheng ; Coyle, Michael P. ; Ernst, Ulrich ; Peters, Robert T. ; Schellenberger, Volker</creator><creatorcontrib>Podust, Vladimir N. ; Balan, Sibu ; Sim, Bee-Cheng ; Coyle, Michael P. ; Ernst, Ulrich ; Peters, Robert T. ; Schellenberger, Volker</creatorcontrib><description>XTEN™ is a class of unstructured hydrophilic, biodegradable protein polymers designed to increase the half-lives of therapeutic peptides and proteins. XTEN polymers and XTEN fusion proteins are typically expressed in Escherichia coli and purified by conventional protein chromatography as monodisperse polypeptides of exact length and sequence. Unstructured XTEN polypeptides have hydrodynamic volumes significantly larger than typical globular proteins of similar mass, thus imparting a bulking effect to the therapeutic payloads attached to them. Since their invention, XTEN polypeptides have been utilized to extend the half-lives of a variety of peptide- and protein-based therapeutics. Multiple clinical and preclinical studies and related drug discovery and development efforts are in progress. This review details the most current understanding of physicochemical properties and biological behavior of XTEN and XTENylated molecules. Additionally, the development path and status of several advanced drug discovery and development efforts are highlighted.
[Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2015.10.038</identifier><identifier>PMID: 26497931</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Biological Products - chemistry ; Biological Products - pharmacokinetics ; Biotherapeutics ; Chemical conjugation ; Clinical Trials as Topic - methods ; Drug Discovery - methods ; Drug Discovery - trends ; Genetic fusion ; Half-Life ; Half-life extension ; Humans ; Peptides ; Polymers - chemistry ; Polymers - pharmacokinetics ; Protein Structure, Secondary ; Proteins - chemistry ; Proteins - pharmacokinetics ; XTEN protein polymer</subject><ispartof>Journal of controlled release, 2016-10, Vol.240, p.52-66</ispartof><rights>2015 The Authors</rights><rights>Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-8b72cd4980fcd3d5a4d13e9b8ccbaa6e229b79ac6148eab96e4018f6395492fa3</citedby><cites>FETCH-LOGICAL-c515t-8b72cd4980fcd3d5a4d13e9b8ccbaa6e229b79ac6148eab96e4018f6395492fa3</cites><orcidid>0000-0002-6134-7484 ; 0000-0002-7710-6060</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168365915302054$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26497931$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Podust, Vladimir N.</creatorcontrib><creatorcontrib>Balan, Sibu</creatorcontrib><creatorcontrib>Sim, Bee-Cheng</creatorcontrib><creatorcontrib>Coyle, Michael P.</creatorcontrib><creatorcontrib>Ernst, Ulrich</creatorcontrib><creatorcontrib>Peters, Robert T.</creatorcontrib><creatorcontrib>Schellenberger, Volker</creatorcontrib><title>Extension of in vivo half-life of biologically active molecules by XTEN protein polymers</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>XTEN™ is a class of unstructured hydrophilic, biodegradable protein polymers designed to increase the half-lives of therapeutic peptides and proteins. XTEN polymers and XTEN fusion proteins are typically expressed in Escherichia coli and purified by conventional protein chromatography as monodisperse polypeptides of exact length and sequence. Unstructured XTEN polypeptides have hydrodynamic volumes significantly larger than typical globular proteins of similar mass, thus imparting a bulking effect to the therapeutic payloads attached to them. Since their invention, XTEN polypeptides have been utilized to extend the half-lives of a variety of peptide- and protein-based therapeutics. Multiple clinical and preclinical studies and related drug discovery and development efforts are in progress. This review details the most current understanding of physicochemical properties and biological behavior of XTEN and XTENylated molecules. Additionally, the development path and status of several advanced drug discovery and development efforts are highlighted.
[Display omitted]</description><subject>Animals</subject><subject>Biological Products - chemistry</subject><subject>Biological Products - pharmacokinetics</subject><subject>Biotherapeutics</subject><subject>Chemical conjugation</subject><subject>Clinical Trials as Topic - methods</subject><subject>Drug Discovery - methods</subject><subject>Drug Discovery - trends</subject><subject>Genetic fusion</subject><subject>Half-Life</subject><subject>Half-life extension</subject><subject>Humans</subject><subject>Peptides</subject><subject>Polymers - chemistry</subject><subject>Polymers - pharmacokinetics</subject><subject>Protein Structure, Secondary</subject><subject>Proteins - chemistry</subject><subject>Proteins - pharmacokinetics</subject><subject>XTEN protein polymer</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1qGzEUhUVpqB23j9CiZTfjSqOfkVYlBOcHQrNxwTuh0dxpZTQjVxqb-O0jYzfbrC4cvqN79SH0lZIlJVT-2C63Lo4JwrImVJRsSZj6gOZUNaziWouPaF44VTEp9Axd57wlhAjGm09oVkuuG83oHG1WLxOM2ccRxx77ER_8IeK_NvRV8D2cwtbHEP94Z0M4YusmfwA8xABuHyDj9og369UvvEtxgtLfxXAcIOXP6Kq3IcOXy1yg33er9e1D9fR8_3h781Q5QcVUqbapXce1Ir3rWCcs7ygD3SrnWmsl1LVuG22dpFyBbbUETqjqJdOC67q3bIG-n98tB_zbQ57M4LODEOwIcZ8NVbWUXDW1Lqg4oy7FnBP0Zpf8YNPRUGJOUs3WXKSak9RTXKSW3rfLin07QPfW-m-xAD_PAJSPHjwkk52H0UHnE7jJdNG_s-IVrkeMGg</recordid><startdate>20161028</startdate><enddate>20161028</enddate><creator>Podust, Vladimir N.</creator><creator>Balan, Sibu</creator><creator>Sim, Bee-Cheng</creator><creator>Coyle, Michael P.</creator><creator>Ernst, Ulrich</creator><creator>Peters, Robert T.</creator><creator>Schellenberger, Volker</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6134-7484</orcidid><orcidid>https://orcid.org/0000-0002-7710-6060</orcidid></search><sort><creationdate>20161028</creationdate><title>Extension of in vivo half-life of biologically active molecules by XTEN protein polymers</title><author>Podust, Vladimir N. ; Balan, Sibu ; Sim, Bee-Cheng ; Coyle, Michael P. ; Ernst, Ulrich ; Peters, Robert T. ; Schellenberger, Volker</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-8b72cd4980fcd3d5a4d13e9b8ccbaa6e229b79ac6148eab96e4018f6395492fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Biological Products - chemistry</topic><topic>Biological Products - pharmacokinetics</topic><topic>Biotherapeutics</topic><topic>Chemical conjugation</topic><topic>Clinical Trials as Topic - methods</topic><topic>Drug Discovery - methods</topic><topic>Drug Discovery - trends</topic><topic>Genetic fusion</topic><topic>Half-Life</topic><topic>Half-life extension</topic><topic>Humans</topic><topic>Peptides</topic><topic>Polymers - chemistry</topic><topic>Polymers - pharmacokinetics</topic><topic>Protein Structure, Secondary</topic><topic>Proteins - chemistry</topic><topic>Proteins - pharmacokinetics</topic><topic>XTEN protein polymer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Podust, Vladimir N.</creatorcontrib><creatorcontrib>Balan, Sibu</creatorcontrib><creatorcontrib>Sim, Bee-Cheng</creatorcontrib><creatorcontrib>Coyle, Michael P.</creatorcontrib><creatorcontrib>Ernst, Ulrich</creatorcontrib><creatorcontrib>Peters, Robert T.</creatorcontrib><creatorcontrib>Schellenberger, Volker</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Podust, Vladimir N.</au><au>Balan, Sibu</au><au>Sim, Bee-Cheng</au><au>Coyle, Michael P.</au><au>Ernst, Ulrich</au><au>Peters, Robert T.</au><au>Schellenberger, Volker</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extension of in vivo half-life of biologically active molecules by XTEN protein polymers</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2016-10-28</date><risdate>2016</risdate><volume>240</volume><spage>52</spage><epage>66</epage><pages>52-66</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>XTEN™ is a class of unstructured hydrophilic, biodegradable protein polymers designed to increase the half-lives of therapeutic peptides and proteins. XTEN polymers and XTEN fusion proteins are typically expressed in Escherichia coli and purified by conventional protein chromatography as monodisperse polypeptides of exact length and sequence. Unstructured XTEN polypeptides have hydrodynamic volumes significantly larger than typical globular proteins of similar mass, thus imparting a bulking effect to the therapeutic payloads attached to them. Since their invention, XTEN polypeptides have been utilized to extend the half-lives of a variety of peptide- and protein-based therapeutics. Multiple clinical and preclinical studies and related drug discovery and development efforts are in progress. This review details the most current understanding of physicochemical properties and biological behavior of XTEN and XTENylated molecules. Additionally, the development path and status of several advanced drug discovery and development efforts are highlighted.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26497931</pmid><doi>10.1016/j.jconrel.2015.10.038</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-6134-7484</orcidid><orcidid>https://orcid.org/0000-0002-7710-6060</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-3659 |
| ispartof | Journal of controlled release, 2016-10, Vol.240, p.52-66 |
| issn | 0168-3659 1873-4995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826648729 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Biological Products - chemistry Biological Products - pharmacokinetics Biotherapeutics Chemical conjugation Clinical Trials as Topic - methods Drug Discovery - methods Drug Discovery - trends Genetic fusion Half-Life Half-life extension Humans Peptides Polymers - chemistry Polymers - pharmacokinetics Protein Structure, Secondary Proteins - chemistry Proteins - pharmacokinetics XTEN protein polymer |
| title | Extension of in vivo half-life of biologically active molecules by XTEN protein polymers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T02%3A47%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extension%20of%20in%20vivo%20half-life%20of%20biologically%20active%20molecules%20by%20XTEN%20protein%20polymers&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Podust,%20Vladimir%20N.&rft.date=2016-10-28&rft.volume=240&rft.spage=52&rft.epage=66&rft.pages=52-66&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2015.10.038&rft_dat=%3Cproquest_cross%3E1826648729%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826648729&rft_id=info:pmid/26497931&rft_els_id=S0168365915302054&rfr_iscdi=true |